Day: September 4, 2025

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Verusa Holding Anonim Sirketi (Borsa Istanbul: VERUS; OTCQX: VRSHF), a Turkish private equity and venture capital investment company, has qualified to trade on the OTCQX® Best Market. Verusa Holding Anonim Sirketi begins trading today on OTCQX under the symbol “VRSHF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information...

TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce results from its Phase 2 drilling program at the 100%-owned Pardo Gold Project, located 65 km northeast of Sudbury, Ontario. The results include the thickest zone of gold-bearing conglomerate reef intersected to date, further confirming the expansion potential of gold mineralization at Pardo. HighlightsHole PD-25-87, starting at a depth of 32 metres, intersected 6.47 metres of 2.16 gpt gold including 2.65 metres of 3.87 gpt gold and a high-grade core returning 0.85 metres of 9.41 gpt gold.This 35-metre step-out to the northwest, intersected the thickest gold-bearing conglomerate reef at Pardo to date and represents the discovery of a new channel of gold mineralization that remains open for drill...

NDA remains on track for FDA PDUFA goal date of January 31, 2026 Commercial planning continues enabling rapid launch following approvalWARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that an advisory committee meeting is not required for Anaphylm™ (dibutepinephrine) Sublingual Film. The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains January 31, 2026. Anaphylm has the potential to be the first and only FDA-approved, non-invasive, orally delivered epinephrine product for the...

TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) — Churchill Resources Inc. (“Churchill” or the “Company”) (TSXV: CRI) is pleased to announce that permits have been approved by the Mineral Lands Division of the Department of Industry, Energy and Technology (“IET”) for all proposed activities on the Black Raven Project at Moreton’s Harbour, Central Newfoundland, host to the past-producing Frost Cove Antimony Mine. Major activities are expected to include:Trenching and drill pad/access trail preparation by local contractor Small’s Construction Ltd. of Twillingate, NL; Property-wide airborne LiDAR surveying by contractor RPM Geospatial of Holyrood, NL; and Core drilling operations are to commence on September 15th in conjunction with the surface trenches, to define the known mineralization at depth by drilling for the first time and follow...

As TSPY surpasses $69 million in AUM, TappAlpha launches TDAQ to bring its daily income strategy to the NASDAQ-100. SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) — TappAlpha, a fintech-powered ETF issuer focused on making advanced investment strategies accessible, announces the launch of the TappAlpha Innovation 100 Growth & Daily Income ETF (Cboe: TDAQ). The launch comes as the firm’s flagship product, the TappAlpha SPY Growth & Daily Income ETF (Nasdaq: TSPY), surpasses $69 million in assets under management (AUM). Since its launch in August 2024, TSPY has gained investor attention with its unique zero-days-to-expiration (0DTE) strategy on the S&P 500. The fund blends S&P 500 participation with a daily covered call overlay, allowing investors to seek additional income while still capturing the returns of SPY. With...

BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on Monday, September 8th, at 4:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current...

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce that it has begun drilling at the Anatacau Main Project, located in the Eeyou-Istchee James Bay region of Quebec. The drill program will target the Anais lithium discovery, located 22 kilometers east and along strike from Rio Tinto’s Galaxy project and BRW’s Anatacau West project. Mr. Killian Charles, President and CEO of BRW, commented: “Beyond our favorable results in Greenland, we continue to advance our portfolio of assets in Quebec. We expect to complete our maiden resource estimate at Mirage in Q4 and, now, have begun an exciting new drill program at Anatacau Main, one of our first Canadian lithium discoveries. Our previous work at the neighbouring Anatacau West project...

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 a.m. ET. Climb Bio’s management team will be joined by leading nephrologist, Craig E. Gordon, MD, MS, who has over 20 years of experience treating patients with IgA nephropathy (IgAN). The event will highlight the Company’s CLYM116 program, a preclinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic B cell activity in autoimmune diseases. CLYM116 is being developed for the treatment of IgAN and is the only known anti-APRIL approach to employ a ‘sweeper’ mechanism of action, which facilitates...